



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Successful Anesthetic Management of Pheochromocytoma in a Patient with Preoperative Hypertension: A Case Report

Faisal Irwanda^{1*}, Novita Anggraeni²

¹Resident of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Riau/Arifin Achmad Regional General Hospital, Pekanbaru, Indonesia

²Department Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Riau/Arifin Achmad Regional General Hospital, Pekanbaru, Indonesia

ARTICLE INFO

Keywords:

Adrenalectomy
Anesthesia
Case Report
Hypertension
Pheochromocytoma

*Corresponding author:

Faisal Irwanda

E-mail address:

irwandafaisal@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i3.1222>

ABSTRACT

Background: Pheochromocytoma, a rare tumor arising from chromaffin cells in the adrenal medulla, poses significant anesthetic challenges due to its propensity to release catecholamines, potentially leading to life-threatening hypertensive crises. This case report describes the successful anesthetic management of a patient with pheochromocytoma presenting with preoperative hypertension. **Case presentation:** A 37-year-old female with a 12x5 cm right adrenal tumor diagnosed as pheochromocytoma was scheduled for adrenalectomy. She presented with a history of uncontrolled hypertension, episodic headaches, diaphoresis, and palpitations. Preoperative management focuses on blood pressure control using alpha and beta-adrenergic blockers. Anesthesia was induced with propofol, fentanyl, and atracurium, while nitroglycerin and sevoflurane were used to maintain hemodynamic stability. The patient's blood pressure was closely monitored throughout the procedure, with interventions made to manage fluctuations during tumor manipulation. **Conclusion:** Successful anesthetic management of pheochromocytoma requires meticulous preoperative preparation, vigilant intraoperative monitoring, and prompt pharmacological interventions. This case highlights the importance of a multidisciplinary approach, including endocrinologists, anesthesiologists, and surgeons, to optimize patient outcomes.

1. Introduction

Pheochromocytoma, a rare neuroendocrine tumor arising from chromaffin cells in the adrenal medulla, presents significant challenges for anesthesiologists due to its potential for catecholamine release and life-threatening hypertensive crises. The incidence of pheochromocytoma is estimated to be approximately 0.8 per 100,000 person-years, with a prevalence of 0.1-0.6% in patients with hypertension. Although typically benign, these tumors can cause significant morbidity and mortality if not managed appropriately during the perioperative period. The hallmark of

pheochromocytoma is the excessive production and secretion of catecholamines, primarily epinephrine and norepinephrine. This catecholamine excess can lead to a wide range of clinical manifestations, including hypertension, tachycardia, headache, diaphoresis, and anxiety. The classic triad of symptoms, consisting of episodic headache, sweating, and tachycardia, is present in only a minority of patients. The clinical presentation of pheochromocytoma can be highly variable, ranging from asymptomatic to life-threatening hypertensive crises.¹⁻³

The diagnosis of pheochromocytoma is based on a combination of clinical suspicion, biochemical testing, and imaging studies. Biochemical tests, such as 24-hour urine collection for fractionated metanephrines and plasma metanephrines, are essential for confirming the diagnosis. Imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), are used to localize the tumor and assess its size and extent. The definitive treatment for pheochromocytoma is surgical resection, preferably laparoscopic adrenalectomy. However, the perioperative management of these patients is complex and requires a multidisciplinary approach involving endocrinologists, anesthesiologists, and surgeons. The primary goals of anesthetic management are to prevent and treat hypertensive crises, maintain hemodynamic stability, and ensure adequate tissue perfusion throughout the perioperative period.⁴⁻⁶

Preoperative optimization is crucial to reduce the risk of intraoperative complications. This includes adequate blood pressure control with alpha- and beta-adrenergic blockers, fluid and electrolyte management, and patient education. Alpha-adrenergic blockade is the cornerstone of preoperative management, effectively controlling blood pressure and reducing the risk of hypertensive crisis during surgery. Beta-adrenergic blockade is typically added after alpha-blockade to control tachycardia and prevent arrhythmias. Intraoperative anesthetic management requires vigilant monitoring and prompt pharmacological interventions. Anesthetic induction, laryngoscopy, and surgical manipulation can trigger catecholamine release, leading to hypertensive crisis. Short-acting vasodilators, such as nitroprusside or nitroglycerin, are essential for managing these hypertensive episodes. Following tumor removal, the sudden decrease in circulating catecholamines can lead to hypotension. This can be managed with fluid boluses and vasopressor support, such as phenylephrine or norepinephrine. Postoperative management focuses on maintaining hemodynamic stability, pain control, and preventing complications.

Patients are typically admitted to the intensive care unit (ICU) for close monitoring and management of potential complications.⁷⁻¹⁰ This case report presents the anesthetic management of a patient with pheochromocytoma who presented with preoperative hypertension.

2. Case Presentation

The patient, a 37-year-old female, presented with a constellation of symptoms suggestive of pheochromocytoma. Her primary complaint was a 3-month history of recurrent headaches, characterized by a throbbing quality and moderate to severe intensity. These headaches were often accompanied by excessive sweating, a symptom she described as "drenching," occurring even at rest or in cool environments. Additionally, she reported experiencing palpitations, described as a rapid, forceful, or irregular heartbeat, which often coincided with the headaches and sweating episodes. The patient also noted increased anxiety and lower back pain, further raising suspicion for a potential hormonal imbalance. Notably, she denied any nausea or vomiting, which can sometimes be associated with pheochromocytoma-induced hypertensive crises. Significantly, the patient had a history of pre-existing hypertension that remained uncontrolled despite ongoing medication. This uncontrolled hypertension, coupled with the other symptoms, prompted further investigation into a possible secondary cause, such as pheochromocytoma. Upon physical examination, the patient's general condition was assessed as good. Her axillary temperature was within the normal range at 36.5°C. However, her blood pressure was significantly elevated at 161/102 mmHg, consistent with her history of uncontrolled hypertension. Her pulse rate was also elevated at 96 bpm, likely reflecting a combination of anxiety and the potential effects of excessive catecholamine secretion. Her respiratory rate was within the normal range at 18 breaths/min. Other systemic examinations, including cardiovascular, respiratory, and neurological assessments, were unremarkable. Laboratory

investigations were conducted to assess the patient's overall health and rule out other potential causes of her symptoms. Serum electrolytes, including sodium, potassium, and chloride, were within normal limits, indicating no significant electrolyte imbalances. Liver function tests, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT), were also normal, suggesting no liver dysfunction. Renal function, as assessed by blood urea nitrogen (BUN) and creatinine levels, was within the normal range, indicating normal kidney function. A complete blood count revealed no abnormalities, with white blood cell count, hemoglobin, and platelet count all within normal limits. Imaging studies played a crucial role in confirming the diagnosis and localizing the tumor. An abdominal ultrasound revealed a 12x5 cm mass in the right adrenal gland, highly suggestive of a pheochromocytoma (Figure 1). This finding corroborated the clinical suspicion based on the patient's symptoms and uncontrolled hypertension. An electrocardiogram (ECG) was performed to assess cardiac function and rhythm, and the results were normal, indicating no significant underlying cardiac abnormalities. A chest X-ray was also conducted to evaluate the lungs and heart, and the findings were unremarkable. Based on the collective findings from the anamnesis, clinical examination, laboratory investigations, and imaging studies, a diagnosis of pheochromocytoma was established. The patient's constellation of symptoms, including recurrent headaches, excessive sweating, palpitations, anxiety, and uncontrolled hypertension, strongly suggested a catecholamine-secreting tumor. The presence of a large adrenal mass on abdominal ultrasound further supported this diagnosis. The case presentation highlights the classic clinical features of pheochromocytoma, including the triad of episodic headache, sweating, and tachycardia. While this triad is not always present, it serves as a crucial diagnostic clue when encountered. The patient's uncontrolled hypertension, despite medication, further emphasized the need to investigate secondary causes of hypertension, such as pheochromocytoma. The

laboratory investigations were essential in ruling out other potential causes of the patient's symptoms and assessing her overall health status. The normal serum electrolytes, liver function, and renal function indicated no significant metabolic abnormalities. The complete blood count was also normal, suggesting no underlying hematologic disorders. The abdominal ultrasound played a critical role in confirming the diagnosis and localizing the tumor to the right adrenal gland. The large size of the tumor (12x5 cm) indicated a significant potential for catecholamine secretion and underscored the importance of careful perioperative management. The normal ECG and chest X-ray helped rule out any significant cardiac or pulmonary complications (Table 1).

Given the diagnosis of pheochromocytoma and the patient's uncontrolled hypertension, a comprehensive preoperative management strategy was implemented to mitigate the risks associated with surgical intervention. The primary goals of this management were to achieve adequate blood pressure control, optimize fluid and electrolyte balance, assess cardiac function, and provide thorough patient education. The cornerstone of preoperative management for pheochromocytoma is the establishment of effective blood pressure control. This is crucial to minimize the risk of intraoperative hypertensive crises, which can be triggered by anesthetic induction, laryngoscopy, and surgical manipulation. In this case, a combination of alpha- and beta-adrenergic blockers was employed to achieve optimal blood pressure regulation. Phenoxybenzamine, a long-acting, non-competitive alpha-adrenergic blocker, was initiated at a dose of 10 mg twice daily. The dose was gradually titrated upwards over two weeks, reaching a final dose of 30 mg twice daily. This gradual titration allowed for the patient's cardiovascular system to adapt to the alpha-blockade, minimizing the risk of postural hypotension and reflex tachycardia. Phenoxybenzamine's non-competitive binding mechanism provided sustained alpha-blockade, ensuring adequate blood pressure control throughout the perioperative period. Metoprolol, a selective beta1-adrenergic blocker, was

added to the regimen after one week of alpha-blockade. This was initiated at a dose of 25 mg twice daily. Beta-blockade was essential to control tachycardia and prevent arrhythmias, which can occur due to unopposed beta-adrenergic stimulation following alpha-blockade. The target blood pressure throughout this preoperative optimization phase was 140/80 mmHg, a level considered safe for proceeding with surgery. Adequate hydration was maintained to ensure optimal intravascular volume and tissue perfusion. This was particularly crucial in the context of alpha-blockade, which can cause vasodilation and potential hypovolemia. The patient's fluid intake and output were closely monitored to assess fluid balance and prevent dehydration or fluid overload. Electrolyte imbalances, particularly hypokalemia, can occur in patients with pheochromocytoma due to the effects of catecholamines on renal potassium excretion. Therefore, serum electrolytes were closely monitored and corrected as needed. Maintaining normoglycemia was also essential, as hypoglycemia can exacerbate the effects of catecholamine excess. A comprehensive cardiac evaluation was performed to assess the impact of chronic catecholamine exposure on the heart. An echocardiogram was conducted to rule out cardiomyopathy or other cardiac complications that could increase the risk of perioperative cardiovascular events. Throughout the preoperative period, the patient's blood pressure and heart rate were regularly monitored to assess the effectiveness of the medical therapy and detect any signs of instability. Additionally, the patient was closely monitored for symptoms such as headaches, sweating, and palpitations, which could indicate inadequate blood pressure control or impending hypertensive crisis. Patient education played a vital role in the preoperative preparation. The patient was provided with a detailed explanation of the surgical procedure, potential complications, and the importance of medication adherence. This education aimed to alleviate anxiety and ensure the patient's active participation in her care. Additionally, the patient was informed about postoperative expectations, including

pain management strategies and the recovery process. The preoperative management strategy employed in this case reflects the current best practices for optimizing patients with pheochromocytoma before surgery. The use of alpha-adrenergic blockade with phenoxybenzamine is considered the cornerstone of preoperative management, effectively controlling blood pressure and reducing the risk of intraoperative hypertensive crises. The gradual titration of phenoxybenzamine allowed for the patient's cardiovascular system to adapt, minimizing the risk of adverse effects. The addition of beta-adrenergic blockade with metoprolol further enhanced blood pressure control and prevented tachycardia and arrhythmias. The target blood pressure of 140/80 mmHg represented a safe level for proceeding with surgery while minimizing the risk of hypotension. Fluid management was crucial to maintain adequate intravascular volume and prevent dehydration, particularly in the context of alpha-blockade. Electrolyte and glucose management ensured metabolic stability, further reducing the risk of perioperative complications. The comprehensive cardiac evaluation, including an echocardiogram, helped assess the impact of chronic catecholamine exposure on the heart and rule out any significant cardiac abnormalities. Regular monitoring of blood pressure, heart rate, and symptoms allowed for prompt detection and management of any signs of instability. Patient education played a vital role in empowering the patient and ensuring her active participation in her care (Table 2).

The anesthetic management of this patient with pheochromocytoma presented unique challenges due to the potential for hemodynamic instability. The primary goals were to maintain stable hemodynamics, prevent and treat hypertensive crises, and ensure adequate tissue perfusion throughout the perioperative period. A multimodal approach was employed, incorporating careful monitoring, individualized anesthetic induction and maintenance, and proactive hemodynamic management. Comprehensive monitoring was essential to ensure

patient safety and guide anesthetic management. Standard monitoring modalities included electrocardiography (ECG) to assess heart rate and rhythm, non-invasive blood pressure monitoring, pulse oximetry to measure oxygen saturation, and capnography to monitor ventilation and end-tidal carbon dioxide levels (Figure 2). An arterial line was placed for continuous blood pressure monitoring, providing real-time data and facilitating rapid intervention in case of hemodynamic fluctuations. Urine output was closely monitored to assess renal perfusion and fluid status. Temperature monitoring was implemented to detect and prevent hypothermia, which can exacerbate hemodynamic instability. Neuromuscular monitoring was used to ensure adequate muscle relaxation and guide the administration of neuromuscular blocking agents. Anesthetic induction was carefully titrated to prevent abrupt hemodynamic changes. Propofol, a short-acting hypnotic agent with minimal cardiovascular effects, was administered at a dose of 2 mg/kg, adjusted based on the patient's response. Fentanyl, an opioid analgesic, was given at 2 mcg/kg to provide analgesia and attenuate the stress response to surgery. Rocuronium, a non-depolarizing neuromuscular blocking agent, was administered at 0.6 mg/kg to facilitate endotracheal intubation. Lidocaine, at a dose of 1.5 mg/kg, was given prior to intubation to attenuate the hemodynamic response associated with laryngoscopy and intubation. Endotracheal intubation was performed using a cuffed endotracheal tube to secure the airway and ensure adequate ventilation. Proper tube placement was confirmed by auscultation of breath sounds bilaterally and capnography. Anesthesia was maintained with sevoflurane, an inhaled anesthetic agent with relatively stable hemodynamic effects, at a concentration of 1-2% in a mixture of oxygen and air. Nitrous oxide, another inhaled anesthetic, was considered for use with caution, only if the patient's hemodynamics remained stable. Opioid analgesics, such as fentanyl or remifentanyl, were titrated to effect to provide adequate analgesia and minimize the need

for high concentrations of volatile anesthetics. Hemodynamic management was a critical aspect of the anesthetic care. The patient's blood pressure was closely monitored throughout the procedure, and interventions were made to manage fluctuations. Nitroprusside, a potent vasodilator with rapid onset and offset, was available for the management of hypertensive episodes. It was prepared for administration as an intravenous infusion at a rate of 0.5-10 mcg/kg/min, titrated to effect. Nitroglycerin, another vasodilator, was considered as an alternative to nitroprusside. In the event of hypotension, fluid boluses of crystalloids or colloids were administered to expand intravascular volume. If fluid therapy proved insufficient, vasopressors such as phenylephrine or norepinephrine were prepared for infusion, titrated to effect to maintain adequate blood pressure. Emergence from anesthesia was managed carefully to avoid coughing and bucking, which could precipitate hemodynamic instability. The neuromuscular blockade was adequately reversed, and the patient was extubated when fully awake and meeting extubation criteria, ensuring adequate spontaneous ventilation and airway protection. The anesthetic management of this patient with pheochromocytoma highlights the importance of a multimodal approach, combining careful monitoring, individualized anesthetic selection, and proactive hemodynamic management. The comprehensive monitoring strategy allowed for continuous assessment of the patient's physiological parameters and facilitated prompt intervention in case of hemodynamic fluctuations. The choice of anesthetic agents was guided by their hemodynamic profiles and the need to minimize fluctuations in blood pressure. Propofol and sevoflurane were selected for their relatively stable cardiovascular effects. The use of lidocaine prior to intubation helped attenuate the hemodynamic response associated with laryngoscopy. The proactive management of hypertension and hypotension was crucial to maintain hemodynamic stability throughout the perioperative period. Nitroprusside and nitroglycerin were readily available to manage

hypertensive episodes, while fluid boluses and vasopressors were prepared to address hypotension. The careful management of emergence and extubation minimized the risk of coughing and bucking, which could have triggered hemodynamic instability. The patient was extubated only when fully awake and meeting extubation criteria, ensuring adequate spontaneous ventilation and airway protection (Table 3).

Following the successful surgical resection of the pheochromocytoma, the patient's postoperative care focused on maintaining hemodynamic stability, providing effective pain control, preventing complications, and ensuring a smooth recovery. A multidisciplinary approach was employed, involving close collaboration between the anesthesia team, surgeons, and endocrinologists. The patient was admitted to the intensive care unit (ICU) for close monitoring and management of potential postoperative complications. Continuous ECG monitoring was employed to assess heart rate and rhythm, and an arterial line remained in place for invasive blood pressure monitoring. Pulse oximetry and capnography were continued to monitor oxygenation and ventilation. Urine output was closely monitored to assess renal function and fluid status. Blood glucose monitoring was performed frequently, especially in the first 24 hours, to detect and manage any fluctuations in blood sugar levels. Electrolyte monitoring was also conducted to identify and correct any imbalances. Hemodynamic stability remained a primary concern in the postoperative period. The preoperative alpha- and beta-blockers were continued to maintain blood pressure control. However, the potential for both hypertension and hypotension existed due to the sudden withdrawal of catecholamines following tumor removal. If hypertension occurred, short-acting vasodilators such as nitroprusside or nitroglycerin were available for prompt intervention. Hypotension was managed initially with fluid resuscitation using crystalloids or colloids. If fluid therapy proved inadequate, vasopressors such as phenylephrine or

norepinephrine were administered to maintain adequate blood pressure and tissue perfusion. Effective pain management was crucial to the patient's comfort and recovery. A multimodal analgesia approach was employed, combining opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and regional anesthesia techniques if applicable. Patient-controlled analgesia (PCA) was considered for optimal pain control, allowing the patient to self-administer analgesics as needed. Close monitoring of blood glucose levels was essential, as fluctuations in blood sugar can occur in the postoperative period. Hypoglycemia was treated promptly with intravenous dextrose as needed. Fluid and electrolyte balance were carefully monitored and maintained. Intake and output were closely monitored, and any fluid or electrolyte losses were replaced appropriately. Deep vein thrombosis (DVT) prophylaxis was implemented to prevent thromboembolic complications. Early mobilization was encouraged to prevent pulmonary complications and promote recovery. The patient's oral intake was gradually resumed as tolerated. Prior to discharge, the patient received comprehensive education on medications, potential complications, and follow-up appointments. Referral to an endocrinologist was arranged for long-term management of pheochromocytoma, including surveillance for recurrence. The postoperative management of this patient with pheochromocytoma highlights the importance of a comprehensive and vigilant approach to ensure a smooth recovery and prevent complications. The ICU admission allowed for close monitoring and prompt management of potential hemodynamic instability, pain, and metabolic derangements. The continuation of alpha- and beta-blockers was crucial in maintaining blood pressure control, while the availability of short-acting vasodilators and vasopressors allowed for the management of both hypertension and hypotension. The multimodal analgesia strategy ensured effective pain control, promoting patient comfort and early mobilization. Close monitoring of blood glucose and electrolytes helped maintain metabolic stability, while

DVT prophylaxis and early mobilization aimed to prevent complications. The comprehensive discharge planning, including patient education and referral to

an endocrinologist, ensured continuity of care and long-term follow-up (Table 4).

Table 1. Anamnesis, clinical findings, laboratory, imaging, and diagnosis.

Category	Findings
Anamnesis	<ul style="list-style-type: none"> - 37-year-old female. - 3-month history of headaches. - Excessive sweating. - Palpitations. - Anxiety. - Lower back pain. - No nausea or vomiting. - Pre-existing hypertension (uncontrolled despite medication).
Clinical examination	<ul style="list-style-type: none"> - General condition: Good. - Axillary temperature: 36.5°C. - Blood pressure: 161/102 mmHg. - Pulse rate: 96 bpm. - Respiratory rate: 18 breaths/min. - Other findings: Within normal limits.
Laboratory investigations	<ul style="list-style-type: none"> - Serum electrolytes: Normal. - Liver function: Normal. - Renal function: Normal. - Complete blood count: Normal.
Imaging	<ul style="list-style-type: none"> - Abdominal ultrasound: 12x5 cm right adrenal tumor (Figure 1). - ECG: Normal. - Chest X-ray: Normal.
Diagnosis	<ul style="list-style-type: none"> - Pheochromocytoma.

Table 2. Preoperative management.

Category	Details
Blood pressure control	<ul style="list-style-type: none"> - Alpha-adrenergic blocker: Phenoxybenzamine. - Initial dose: 10 mg twice daily. - Titration: Gradually increased to 30 mg twice daily over 2 weeks. - Beta-adrenergic blocker: Metoprolol. - Dose: 25 mg twice daily. - Initiation: Added after 1 week of alpha-blockade. - Target blood pressure: 140/80 mmHg.
Fluid management	<ul style="list-style-type: none"> - Adequate hydration to maintain intravascular volume. - Monitoring for signs of fluid overload or dehydration.
Electrolyte and glucose management	<ul style="list-style-type: none"> - Monitoring and correction of electrolyte imbalances (e.g., hypokalemia). - Maintaining normoglycemia to prevent hypoglycemia
Cardiac evaluation	<ul style="list-style-type: none"> - Assessment of cardiac function (e.g., echocardiogram) to rule out cardiomyopathy or other cardiac complications
Monitoring	<ul style="list-style-type: none"> - Regular blood pressure and heart rate monitoring. - Assessment of symptoms (e.g., headaches, sweating, palpitations)
Patient education	<ul style="list-style-type: none"> - Explanation of the procedure and potential complications. - Importance of medication adherence. - Postoperative expectations

Table 3. Anesthetic management.

Category	Details
Monitoring	- Standard monitoring: ECG, non-invasive blood pressure, pulse oximetry, capnography (Figure 2). - Arterial line: For continuous blood pressure monitoring. - Urine output monitoring. - Temperature monitoring. - Neuromuscular monitoring.
Induction	- Propofol: 2 mg/kg (adjusted based on patient response). - Fentanyl: 2 mcg/kg (adjusted based on patient response). - Rocuronium: 0.6 mg/kg (adjusted based on patient response). - Lidocaine: 1.5 mg/kg (to attenuate hemodynamic response to intubation).
Intubation	- Endotracheal intubation: Using a cuffed endotracheal tube. - Verification of tube placement: Auscultation and capnography.
Maintenance	- Sevoflurane: 1-2% in oxygen and air. - Nitrous oxide: May be used with caution (if hemodynamics are stable). - Opioid analgesics (e.g., fentanyl, remifentanyl): Titrated to effect.
Hemodynamic management	- Hypertension: - Nitroprusside: 0.5-10 mcg/kg/min IV infusion (titrated to effect). - Nitroglycerin: Alternative to nitroprusside. - Hypotension: - Fluid boluses: Crystalloids or colloids. - Vasopressors: Phenylephrine or norepinephrine infusion (titrated to effect).
Emergence and extubation	- Smooth emergence to avoid coughing and bucking. - Adequate reversal of neuromuscular blockade. - Extubation when the patient is fully awake and meets extubation criteria.

Table 4. Postoperative management.

Category	Details
Monitoring	- Intensive care unit (ICU) admission for close monitoring. - Continuous ECG monitoring. - Invasive blood pressure monitoring (arterial line). - Pulse oximetry and capnography. - Urine output monitoring. - Blood glucose monitoring (frequent checks, especially in the first 24 hours). - Electrolyte monitoring.
Hemodynamic management	- Hypertension: - Continue preoperative alpha- and beta-blockers. - Short-acting vasodilators (e.g., nitroprusside, nitroglycerin) if needed. - Hypotension: - Fluid resuscitation (crystalloids or colloids). - Vasopressors (e.g., phenylephrine, norepinephrine) if fluid resuscitation is inadequate.
Pain management	- Multimodal analgesia: Opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and regional anesthesia techniques (if applicable). - Patient-controlled analgesia (PCA) for optimal pain control.
Glycemic control	- Close monitoring of blood glucose levels. - Treatment of hypoglycemia with intravenous dextrose as needed.
Fluid and electrolyte balance	- Monitoring of intake and output. - Replacement of fluid and electrolyte losses.
Other interventions	- Deep vein thrombosis (DVT) prophylaxis. - Early mobilization to prevent pulmonary complications. - Gradual resumption of oral intake as tolerated.
Discharge planning	- Patient education on medications, potential complications, and follow-up appointments. - Referral to endocrinology for long-term management of pheochromocytoma.



Figure 1. Adrenal tumor.




Figure 2. Haemodynamic intraoperative.

3. Discussion

Preoperative optimization is a critical phase in the management of patients with pheochromocytoma, a rare neuroendocrine tumor that arises from chromaffin cells in the adrenal medulla. This tumor is notorious for its ability to release catecholamines, such as epinephrine and norepinephrine, into the

bloodstream, potentially leading to life-threatening hypertensive crises. The primary goals of preoperative optimization are to stabilize the patient's hemodynamic status, mitigate the risk of intraoperative complications, and ensure a smooth and successful surgical procedure. The cornerstone of preoperative optimization is achieving adequate blood

pressure control. This is paramount due to the propensity of pheochromocytomas to cause episodic hypertension, which, if left uncontrolled, can lead to severe cardiovascular complications during surgery. The primary means of achieving blood pressure control is through the use of alpha-adrenergic blockers, such as phenoxybenzamine or doxazosin. These medications directly counteract the effects of catecholamines, reducing vascular tone and lowering blood pressure. Once alpha-blockade is established, beta-adrenergic blockers, such as metoprolol or propranolol, may be added to further control heart rate and prevent arrhythmias. The target blood pressure during preoperative optimization is typically around 140/80 mmHg, a level that balances the need to control hypertension with the risk of inducing hypotension. Maintaining proper fluid and electrolyte balance is another crucial aspect of preoperative optimization. Patients with pheochromocytoma may experience fluid shifts and electrolyte disturbances due to the effects of catecholamines on the kidneys and vascular system. Hypovolemia, or decreased blood volume, can occur due to the vasoconstrictive effects of catecholamines, while hypokalemia, or low potassium levels, may result from increased potassium excretion by the kidneys. Careful monitoring of fluid intake and output, along with regular blood tests to assess electrolyte levels, are essential to ensure that any imbalances are promptly corrected. A comprehensive cardiac evaluation is often necessary to assess the potential impact of chronic catecholamine exposure on the heart. Prolonged exposure to high levels of catecholamines can lead to cardiac complications, such as cardiomyopathy, a condition where the heart muscle becomes weakened and enlarged. An echocardiogram, an ultrasound of the heart, is commonly performed to evaluate the heart's structure and function, helping to identify any underlying cardiac abnormalities that may increase the risk of perioperative cardiovascular events. Patient education plays a vital role in preoperative optimization. It empowers patients to actively participate in their care and reduces anxiety

surrounding the surgical procedure. Clear and thorough explanations of the procedure, potential complications, and the importance of medication adherence are crucial. Patients should also be informed about postoperative expectations, including pain management strategies and the recovery process. This education not only helps patients feel more at ease but also fosters a sense of collaboration between the patient and the healthcare team. Alpha-adrenergic blockade is the cornerstone of pharmacologic management in patients with pheochromocytoma. It is particularly crucial during the preoperative period to mitigate the risk of hypertensive crises, which can be triggered by various stressors associated with surgery, such as anxiety, pain, and surgical manipulation. Alpha-adrenergic blockers work by binding to alpha-adrenergic receptors, preventing catecholamines from binding and exerting their vasoconstrictive effects. This results in vasodilation, reducing blood pressure and minimizing the risk of hypertensive surges. The choice of alpha-blocker depends on various factors, including the patient's clinical presentation, comorbidities, and the preferences of the healthcare team. Phenoxybenzamine, a long-acting, non-competitive alpha-blocker, has been a mainstay in preoperative management for many years. Its non-competitive binding mechanism provides sustained alpha-blockade, ensuring adequate blood pressure control throughout the perioperative period. However, phenoxybenzamine has a relatively slow onset of action and can cause orthostatic hypotension, a condition where blood pressure drops significantly upon standing. In recent years, doxazosin, a selective alpha-1-blocker, has emerged as a viable alternative for preoperative alpha-blockade. Doxazosin has a faster onset of action and is less likely to cause orthostatic hypotension compared to phenoxybenzamine. It is also available in a once-daily formulation, which may improve patient adherence. The titration of alpha-blockers is a critical aspect of preoperative management. The goal is to achieve adequate blood pressure control without inducing excessive hypotension. The starting dose of the alpha-

blocker is typically low and is gradually increased over several days or weeks, allowing the patient's cardiovascular system to adapt to the alpha-blockade. During this titration period, close monitoring of blood pressure and heart rate is essential to assess the effectiveness of the medication and detect any signs of instability. Alpha-blockers can cause a variety of side effects, including orthostatic hypotension, nasal congestion, and reflex tachycardia. Orthostatic hypotension can be minimized by gradual titration of the medication and advising patients to change positions slowly. Nasal congestion can be managed with over-the-counter decongestants, while reflex tachycardia may require the addition of a beta-blocker. Fluid and electrolyte management is another critical component of preoperative optimization in patients with pheochromocytoma. The goal is to ensure that the patient is euvolemic, meaning they have an adequate circulating blood volume, and that their electrolyte levels are within the normal range. Patients with pheochromocytoma may be hypovolemic due to the vasoconstrictive effects of catecholamines. This can be exacerbated by the use of alpha-blockers, which can cause vasodilation and further decrease blood volume. To prevent hypovolemia, adequate hydration is essential. Patients are encouraged to maintain good oral fluid intake, and intravenous fluids may be administered as needed. Close monitoring of fluid intake and output, along with regular assessments of blood pressure and heart rate, can help guide fluid management. Electrolyte imbalances, particularly hypokalemia, are common in patients with pheochromocytoma. Catecholamines can increase potassium excretion by the kidneys, leading to low potassium levels. Hypokalemia can increase the risk of cardiac arrhythmias, especially in patients with underlying heart conditions. Regular monitoring of serum electrolytes, particularly potassium, is essential. If hypokalemia is detected, oral or intravenous potassium supplementation may be necessary to correct the imbalance. Close monitoring of fluid and electrolyte status is crucial throughout the preoperative period. This includes regular

assessments of blood pressure, heart rate, fluid intake and output, and serum electrolyte levels. Any signs of fluid or electrolyte imbalance should be promptly addressed to minimize the risk of perioperative complications. Patient education is an integral part of preoperative optimization. It empowers patients to actively participate in their care, reduces anxiety, and improves adherence to treatment plans. Patients with pheochromocytoma should receive a clear and thorough explanation of the surgical procedure, including the risks and benefits. They should also be informed about potential complications, such as bleeding, infection, and damage to surrounding organs. This information helps patients make informed decisions about their care and prepares them for the postoperative recovery process. Medication adherence is crucial in the management of pheochromocytoma. Patients need to understand the importance of taking their medications as prescribed, even if they are feeling well. Failure to adhere to medication regimens can lead to uncontrolled blood pressure and an increased risk of intraoperative complications. Patients with pheochromocytoma often experience anxiety and fear surrounding their diagnosis and upcoming surgery. It is essential to address their concerns and provide emotional support. Encouraging patients to ask questions and express their feelings can help alleviate anxiety and foster a sense of trust between the patient and the healthcare team. Patients should receive clear instructions on postoperative care, including pain management strategies, wound care, and activity restrictions. They should also be informed about potential postoperative complications and when to seek medical attention. Providing written instructions and answering patient questions can help ensure a smooth and successful recovery.¹¹⁻¹⁴

Intraoperative anesthetic management of patients with pheochromocytoma requires meticulous attention to detail and a thorough understanding of the physiologic perturbations that can occur during surgery. The primary goals of intraoperative management are to maintain hemodynamic stability,

prevent and treat hypertensive crises, and ensure adequate tissue perfusion throughout the procedure. Continuous hemodynamic monitoring is crucial during the intraoperative period. This includes electrocardiography (ECG) to monitor heart rate and rhythm, invasive blood pressure monitoring via an arterial line, pulse oximetry to measure oxygen saturation, and capnography to monitor ventilation and end-tidal carbon dioxide levels. These monitoring modalities provide real-time information about the patient's cardiovascular and respiratory status, allowing for prompt detection and management of any hemodynamic derangements. Anesthetic induction is a critical phase in the intraoperative management of patients with pheochromocytoma. The choice of anesthetic agents and the technique of induction should be carefully considered to minimize hemodynamic fluctuations. Propofol, a short-acting hypnotic agent with minimal cardiovascular effects, is often preferred for induction. It can be administered intravenously at a carefully titrated dose to induce a smooth and controlled loss of consciousness. Opioid analgesics, such as fentanyl or remifentanyl, are used to provide analgesia and attenuate the stress response to surgery. These agents can also help to blunt the hemodynamic response to laryngoscopy and intubation. Neuromuscular blocking agents, such as rocuronium or vecuronium, are used to facilitate endotracheal intubation and ensure adequate muscle relaxation during surgery. Securing the airway is a critical step in the anesthetic management of any patient, and those with pheochromocytoma are no exception. Endotracheal intubation is typically performed to ensure adequate ventilation and oxygenation during the procedure. Laryngoscopy and intubation can stimulate the sympathetic nervous system, potentially leading to hypertension and tachycardia. To mitigate this risk, lidocaine may be administered prior to intubation to attenuate the hemodynamic response. Once the patient is intubated and hemodynamically stable, anesthesia is maintained with a combination of inhaled and intravenous agents. Sevoflurane, an inhaled

anesthetic agent with relatively stable hemodynamic effects, is often used for maintenance. It can be titrated to achieve the desired depth of anesthesia while minimizing hemodynamic fluctuations. Opioid analgesics and sedatives may be used intravenously to provide additional analgesia and sedation as needed. Hypertensive crises are a significant concern during the intraoperative management of patients with pheochromocytoma. Anesthetic induction, laryngoscopy, surgical manipulation, and even mild stress can trigger catecholamine release, leading to abrupt and potentially dangerous increases in blood pressure. Short-acting vasodilators, such as nitroprusside or nitroglycerin, are essential for managing hypertensive episodes. These agents can be administered intravenously to rapidly lower blood pressure and restore hemodynamic stability. The titration of vasodilators requires careful monitoring of blood pressure and other hemodynamic parameters. The goal is to lower blood pressure to a safe level without inducing hypotension. Hypotension can occur during surgery for various reasons, including blood loss, anesthetic agents, and the sudden decrease in circulating catecholamines following tumor removal. Fluid boluses of crystalloids or colloids are often the first-line treatment for hypotension. These fluids help to expand intravascular volume and improve blood pressure. If fluid resuscitation alone is insufficient to restore blood pressure, vasopressors such as phenylephrine or norepinephrine may be administered. These agents stimulate the sympathetic nervous system, increasing vascular tone and raising blood pressure. Emergence from anesthesia is another critical phase in the intraoperative management of patients with pheochromocytoma. Careful planning and execution are essential to minimize the risk of hemodynamic instability. The goal is to achieve a smooth and controlled emergence from anesthesia, avoiding coughing and bucking, which can precipitate hemodynamic fluctuations. Neuromuscular blockade should be adequately reversed before extubation to ensure that the patient has adequate spontaneous ventilation and airway protection. Extubation should

only be performed when the patient is fully awake, meets specific extubation criteria, and is hemodynamically stable.¹⁵⁻¹⁷

Postoperative management of patients who have undergone surgery for pheochromocytoma is a critical period that requires close monitoring and careful management to ensure a smooth recovery and prevent complications. The physiologic changes that occur following tumor removal can lead to a variety of challenges, including hemodynamic instability, pain, and electrolyte imbalances. Patients are typically admitted to the ICU after pheochromocytoma surgery for close monitoring and management of potential complications. The ICU provides a setting with advanced monitoring capabilities and experienced healthcare professionals who can promptly address any emergent issues. Continuous hemodynamic monitoring is essential in the postoperative period. This includes ECG monitoring to assess heart rate and rhythm, invasive blood pressure monitoring via an arterial line, pulse oximetry to measure oxygen saturation, and capnography to monitor ventilation. These monitoring tools allow for early detection and prompt management of hemodynamic instability, which can manifest as either hypertension or hypotension. Although the primary concern in the preoperative period is managing hypertension, it can still occur postoperatively due to residual catecholamines or the stress response to surgery. If hypertension occurs, short-acting vasodilators such as nitroprusside or nitroglycerin can be used to rapidly lower blood pressure. Hypotension is a common complication in the postoperative period due to the sudden withdrawal of catecholamines following tumor removal. This can lead to decreased vascular tone and reduced cardiac output. Fluid resuscitation with crystalloids or colloids is often the first-line treatment for hypotension. If fluid therapy alone is insufficient, vasopressors such as phenylephrine or norepinephrine may be required to restore blood pressure and maintain adequate tissue perfusion. Effective pain management is crucial for patient comfort and recovery. A multimodal analgesia

approach is often employed, combining opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and regional anesthesia techniques if applicable. Patient-controlled analgesia (PCA) can be considered to allow patients to self-administer pain medication as needed, providing a sense of control and optimizing pain relief. Fluid and electrolyte balance must be closely monitored and maintained in the postoperative period. Accurate assessment of fluid intake and output, along with regular monitoring of serum electrolytes, is essential to detect and correct any imbalances. Hypokalemia, in particular, can occur due to the effects of catecholamines on renal potassium excretion and may require potassium supplementation. Close monitoring of blood glucose levels is also important, as fluctuations in blood sugar can occur in the postoperative period. Hypoglycemia can exacerbate the effects of catecholamine excess and should be treated promptly with intravenous dextrose as needed. In addition to hemodynamic instability, pain, and electrolyte imbalances, several other complications can occur in the postoperative period. Deep vein thrombosis (DVT) prophylaxis with anticoagulant medications and early mobilization are important to prevent thromboembolic events. Pulmonary complications, such as pneumonia and atelectasis, can be minimized by encouraging deep breathing exercises and early ambulation. Prior to discharge, patients should receive comprehensive education on medications, potential complications, and follow-up appointments. Referral to an endocrinologist is essential for long-term management of pheochromocytoma, including surveillance for recurrence. Patients should be counseled on lifestyle modifications, such as stress management techniques and dietary changes, to promote overall well-being. Long-term follow-up with an endocrinologist is crucial for patients who have undergone surgery for pheochromocytoma. Regular monitoring for recurrence, hormonal imbalances, and other potential complications is essential to ensure continued health and well-being.¹⁸⁻²⁰

4. Conclusion

This case report presents the successful anesthetic management of a 37-year-old female with pheochromocytoma and preoperative hypertension. The patient's uncontrolled hypertension, episodic headaches, diaphoresis, and palpitations posed significant anesthetic challenges due to the potential for catecholamine release and hypertensive crises. Meticulous preoperative preparation, including alpha and beta-adrenergic blockade, was crucial in stabilizing her blood pressure and reducing the risk of intraoperative complications. The use of propofol, fentanyl, and atracurium for anesthesia induction, along with nitroglycerin and sevoflurane for maintenance, ensured hemodynamic stability throughout the procedure. Continuous monitoring and prompt pharmacological interventions were essential in managing blood pressure fluctuations, particularly during tumor manipulation. This case highlights the importance of a multidisciplinary approach involving endocrinologists, anesthesiologists, and surgeons in the successful management of pheochromocytoma. Careful preoperative optimization, including blood pressure control, fluid and electrolyte management, and patient education, is vital for reducing the risk of intraoperative complications. Intraoperative vigilance and prompt pharmacological interventions are necessary to maintain hemodynamic stability and prevent hypertensive crises. By adhering to these principles, we achieved optimal outcomes in this patient with pheochromocytoma and preoperative hypertension. This case report emphasizes the importance of a comprehensive and individualized approach to anesthetic management, tailored to the unique challenges posed by this rare condition.

5. References

1. Mita K, Tsugita K, Yasuda Y, Matsuki Y, Obata Y, Matsuki Y, et al. A successfully treated case of cardiac arrest after Caesarean section complicated by pheochromocytoma crisis and amniotic fluid embolism. *J Anesth.* 2017; 31(1): 140–3.
2. Saran JS, Moalem J, Schoeniger L, Tzimas K. Perioperative management of pheochromocytoma resection in a patient with severe aortic stenosis. *J Cardiothorac Vasc Anesth.* 2018; 32(6): 2712–5.
3. Naranjo J, Dodd S, Martin YN. Perioperative management of pheochromocytoma. *J Cardiothorac Vasc Anesth.* 2017; 31(4): 1427–39.
4. Yu M, Han C, Zhou Q, Liu C, Ding Z. Clinical effects of prophylactic use of phentolamine in patients undergoing pheochromocytoma surgery. *J Clin Anesth.* 2018; 44: 119.
5. Saran JS, Moalem J, Schoeniger L, Tzimas K. Perioperative management of pheochromocytoma resection in a patient with severe aortic stenosis. *J Cardiothorac Vasc Anesth.* 2018; 32(6): 2712–5.
6. Yu M, Han C, Zhou Q, Liu C, Ding Z. Clinical effects of prophylactic use of phentolamine in patients undergoing pheochromocytoma surgery. *J Clin Anesth.* 2018; 44: 119.
7. Grocott HP. Perioperative considerations in the management of pheochromocytoma: The details behind the changing dogma. *J Cardiothorac Vasc Anesth.* 2018; 32(1): e11–2.
8. Agrelo JC. A rare case of adrenal pheochromocytoma discovered by accident in a CT scan. *J Anesth Crit Care.* 2018; 10(4): 121–2.
9. Kurian DJ, Li AX, Rao S, Konstantinidis A, Roman SA, Kertai MD. Echocardiographic guidance for surgical excision of the intracardiac component of a pheochromocytoma. *Semin Cardiothorac Vasc Anesth.* 2018; 22(3): 324–7.
10. Bala R, Seelwal D, Vashisht G, Kiran S. Pheochromocytoma in pregnancy: a perilous coexistence. *Res Opin Anesth Intensive Care.* 2019; 6(2): 249.

11. M Donaldson C. Pheochromocytoma crisis during routine hysterectomy: a case report and clinical review. *J Anesth Intensive Care Med.* 2019; 9(3).
12. Sherburne R, Urits I, Barr J, Urman RD, Kaye AD, Viswanath O. Hemodynamic volatility that can result from suboptimal preoperative optimization complicated by Fontan physiology during a pheochromocytoma removal. *J Clin Anesth.* 2020; 65(109828): 109828.
13. Cummings JJ, Siegrist KK, Deegan RJ, Solórzano CC, Eagle SS. Robotic adrenalectomy for pheochromocytoma in a patient with Fontan physiology. *J Cardiothorac Vasc Anesth.* 2020; 34(9): 2446–51.
14. Liu Y, Wang B. The relationship between preoperative preparation and intraoperative hypotension of patients undergoing laparoscopic pheochromocytoma resection: a retrospective study. *J Clin Anesth.* 2020; 64(109794): 109794.
15. Kong H, Li N, Yang X-C, Nie X-L, Tian J, Wang D-X. Nonselective compared with selective α -blockade is associated with less intraoperative hypertension in patients with pheochromocytomas and paragangliomas: a retrospective cohort study with propensity score matching. *Anesth Analg.* 2021; 132(1): 140–9.
16. Attisani M, Pocar M, Brenna D, Marro M, Rinaldi M, Boffini M. Extracorporeal membrane oxygenation with ventricular unloading allows for immediate adrenergic blockage in pheochromocytoma-induced cardiogenic shock. *J Cardiothorac Vasc Anesth.* 2021; 35(10): 3039–41.
17. Stombaugh DK, Thomas C, Dalton A, Chaney MA, Nunnally ME, Berends AMA, et al. Pheochromocytoma resection in a patient with chronic thromboembolic pulmonary hypertension and thrombocytopenia. *J Cardiothorac Vasc Anesth.* 2021; 35(11): 3423–33.
18. Hara M, Hyodo A, Kimura H, Hiraki T. Transfenestration Doppler assessment during laparoscopic pheochromocytoma resection in a patient with Fontan circulation. *J Cardiothorac Vasc Anesth.* 2022; 36(9): 3655–61.
19. Efremov S, Alexeev M, Kuleshov O, Safronov A, Ryndin V, Rebrova D, et al. Prognostic model for vasopressor requirement after retroperitoneal adrenalectomy for pheochromocytoma: a retrospective study. *J Cardiothorac Vasc Anesth.* 2023; 37(7): 1230–5.
20. Edgren H, Kristenson K, Törnudd M, Kotán R, Nygren A. Cardiac arrest in a patient unveils pheochromocytoma with rare clinical manifestation requiring extracorporeal membrane oxygenation and urgent surgery. *J Cardiothorac Vasc Anesth.* 2024; 38(11): 2742–6.